Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Medical Genetics · Alpha-1 Antitrypsin Deficiency

Your Genetic Blueprint: Decoding PiZZ, PiSZ, and PiMZ

At a Glance

Your Alpha-1 Antitrypsin Deficiency (AATD) lab report reveals your specific genotype, such as PiZZ, PiSZ, or PiMZ. This genetic blueprint determines your protective protein levels and predicts your lifelong risk for developing lung and liver disease.

Your genetic lab report is the “blueprint” of your Alpha-1 Antitrypsin Deficiency (AATD). It explains why your body isn’t producing enough protective protein and helps your doctors predict your future health risks [1][2]. All of this centers on the SERPINA1 gene, which is responsible for creating the Alpha-1 Antitrypsin (AAT) protein [3].

Common Genotypes

AATD is an autosomal codominant condition, meaning you inherit one “allele” (a version of the gene) from each parent. These letters combine to form your genotype [3][4]. To understand your deficiency, it is helpful to know what a “normal” blueprint looks like:

  • PiMM (Normal): This is the normal, “wild-type” genotype [3]. People with PiMM have normal levels of protective AAT protein and do not face an increased risk of AATD-related lung or liver disease.
  • PiZZ (Severe Deficiency): This is the most serious form of AATD [5][3]. People with this genotype have the lowest levels of protective protein in their blood and are at the highest risk for both lung and liver disease [6][7].
  • PiSZ (Moderate Deficiency): This genotype usually results in higher protein levels than PiZZ and a lower overall risk for emphysema [8][9]. However, PiSZ individuals are still at risk, particularly if they smoke or are exposed to environmental pollutants [9][1].
  • PiMZ (The “Carrier”): PiMZ individuals have one normal (M) allele and one Z allele [10]. While they often have enough protein to protect their lungs, they are at a significantly higher risk for COPD if they are smokers [10][11].

Visualizing the Risks

The following table summarizes the primary genotypes and their associated risks:

Genotype AAT Protein Level Lung Risk (if non-smoker) Lung Risk (if smoker) Liver Risk
PiMM Normal Low Moderate Low
PiMZ Lower than normal Low High Low/Moderate
PiSZ Low Moderate Very High Moderate
PiZZ Extremely Low Very High Extremely High High

How PiZZ Affects Your Body

The PiZZ genotype creates a “double-edged sword” effect in the body through two different biological mechanisms:

1. In the Lungs: A Loss of Protection

The mutation in the PiZZ genotype means very little functional AAT protein ever reaches the lungs [12][13]. Without this “shield,” an enzyme called neutrophil elastase is free to attack and break down the elastic fibers of the lung tissue [12][14]. This is known as a loss-of-function mechanism, leading to the development of panacinar emphysema [15][16].

2. In the Liver: A Toxic Build-up

Unlike the lungs, the liver’s problem isn’t a lack of protein, but rather the shape of the protein it creates. The Z-mutation causes the AAT protein to misfold and “polymerize” (clump together) [17][18]. These clumps get physically stuck inside the liver cells (hepatocytes), causing stress, inflammation, and scarring [19][20]. This is called a toxic gain-of-function and can eventually lead to cirrhosis or liver cancer [17][18].

Reading Your Lab Report

When you look at your results, keep an eye out for these key terms:

  • Alleles: Look for the letters (M, S, Z, or “Null/Q0”). M is normal, while S and Z are the most common deficiency alleles [1][21].
  • Serum AAT Level: This is a number representing how much protein is in your blood [1][22]. Levels below the “protective threshold” (often around 11 micromolar, or roughly 57 mg/dL depending on the lab’s measurement system) indicate a higher risk for lung damage [23].
  • Phenotype vs. Genotype: A genotype report looks at your DNA, while a phenotype report looks at how the protein actually appears in your blood [1][22]. Both are often used to confirm a diagnosis.

Understanding your specific genotype is the first step in creating a personalized “protection plan” for your lungs and liver [24][25].

Common questions in this guide

What is the difference between the PiZZ and PiMZ genotypes?
The PiZZ genotype is a severe deficiency where both inherited genes are mutated, leading to very low protective protein levels and a high risk for lung and liver disease. The PiMZ genotype means you are a carrier with one normal gene, which usually provides enough protein to protect the lungs unless you smoke.
What does a toxic gain-of-function mean for my liver?
In Alpha-1 Antitrypsin Deficiency, the mutated liver protein misfolds and clumps together inside liver cells. This toxic buildup causes stress, inflammation, and scarring, which can eventually lead to cirrhosis or liver disease over time.
What is the protective threshold for AAT protein levels?
The protective threshold is the minimum amount of Alpha-1 Antitrypsin protein needed in your blood to protect your lungs from damage. This is generally considered to be around 11 micromolar, or roughly 57 mg/dL, depending on the laboratory.
What is the difference between an AAT genotype and phenotype?
A genotype test looks directly at your DNA to identify the specific SERPINA1 gene mutations you inherited. A phenotype test examines how the actual Alpha-1 protein behaves and appears in your blood. Both are used to confirm an AATD diagnosis.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.My lab report says I am Pi[Insert Your Genotype]—what does this specific combination of alleles mean for my long-term lung and liver risk?
  2. 2.What was my measured serum AAT level, and how does it compare to the 'protective threshold' (usually around 11 micromolar or 57 mg/dL)?
  3. 3.Does my genotype put me at a higher risk for liver 'toxic gain-of-function' (protein clumping), and what tests should we use to monitor this?
  4. 4.Is my genotype considered 'severe' enough to qualify for augmentation therapy if my lung function starts to decline?
  5. 5.Does my report show any 'null' alleles or rare variants that might require more specialized monitoring?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can Alpha-1 PiMZ Carriers Get COPD If They Don't Smoke?Does Alpha-1 Always Affect Both Lungs and Liver?How to Read Your Alpha-1 Lab Results

References

References (25)
  1. 1

    Pulmonary manifestations of alpha 1 antitrypsin deficiency.

    Mulkareddy V, Roman J

    The American journal of the medical sciences 2024; (368(1)):1-8 doi:10.1016/j.amjms.2024.04.002.

    PMID: 38599244
  2. 2

    An unusual case of alpha-1-antitrypsin deficiency: SZ/Z.

    Speevak MD, DeMarco ML, Wiebe NS, Chapman KR

    Clinical biochemistry 2019; (64()):49-52 doi:10.1016/j.clinbiochem.2018.12.008.

    PMID: 30579752
  3. 3

    Future Perspectives in the Diagnosis and Treatment of Liver Disease Associated with Alpha-1 Antitrypsin Deficiency.

    Abreu N, Pereira VM, Pestana M, Jasmins L

    GE Portuguese journal of gastroenterology 2023; (30(5)):327-335 doi:10.1159/000528809.

    PMID: 37868641
  4. 4

    Variants of SERPINA1 and the increasing complexity of testing for alpha-1 antitrypsin deficiency.

    Foil KE

    Therapeutic advances in chronic disease 2021; (12_suppl()):20406223211015954 doi:10.1177/20406223211015954.

    PMID: 34408833
  5. 5

    Alpha-1 antitrypsin deficiency: A re-surfacing adult liver disorder.

    Fromme M, Schneider CV, Trautwein C, et al.

    Journal of hepatology 2022; (76(4)):946-958 doi:10.1016/j.jhep.2021.11.022.

    PMID: 34848258
  6. 6

    Fazirsiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease findings from the SEQUOIA phase 2 trial.

    Liaquat T, Malik BT, Hashmi TH, et al.

    Annals of medicine and surgery (2012) 2025; (87(7)):4014-4016 doi:10.1097/MS9.0000000000003393.

    PMID: 40851970
  7. 7

    Alpha-1 Antitrypsin Screening in a Selected Cohort of Patients Affected by Chronic Pulmonary Diseases in Naples, Italy.

    Annunziata A, Ferrarotti I, Coppola A, et al.

    Journal of clinical medicine 2021; (10(8)) doi:10.3390/jcm10081546.

    PMID: 33916947
  8. 8

    Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ.

    Bernhard N, Lepper PM, Vogelmeier C, et al.

    Respiratory medicine 2017; (130()):1-8 doi:10.1016/j.rmed.2017.07.004.

    PMID: 29206626
  9. 9

    Progression and Augmentation Therapy in PiSZ and PiZZ Alpha-1 Antitrypsin Deficiency: A Longitudinal Functional and Densitometric Study.

    Esmaili S, Rodríguez Hermosa JL, Vargas Centanaro G, et al.

    Biomolecules 2025; (15(4)) doi:10.3390/biom15040599.

    PMID: 40305326
  10. 10

    SZ alpha-1 antitrypsin deficiency and pulmonary disease: more like MZ, not like ZZ.

    Franciosi AN, Carroll TP, McElvaney NG

    Thorax 2021; (76(3)):298-301 doi:10.1136/thoraxjnl-2020-215250.

    PMID: 32917839
  11. 11

    Alpha-1 Antitrypsin PiMZ Genotype Is Associated with Chronic Obstructive Pulmonary Disease in Two Racial Groups.

    Foreman MG, Wilson C, DeMeo DL, et al.

    Annals of the American Thoracic Society 2017; (14(8)):1280-1287 doi:10.1513/AnnalsATS.201611-838OC.

    PMID: 28380308
  12. 12

    Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.

    Rahaghi FF, Miravitlles M

    Respiratory research 2017; (18(1)):105 doi:10.1186/s12931-017-0574-1.

    PMID: 28558837
  13. 13

    The Role of Neutrophils in Alpha-1 Antitrypsin Deficiency.

    McCarthy C, Reeves EP, McElvaney NG

    Annals of the American Thoracic Society 2016; (13 Suppl 4()):S297-304 doi:10.1513/AnnalsATS.201509-634KV.

    PMID: 27564664
  14. 14

    The Role of Computed Tomography for the Evaluation of Lung Disease in Alpha-1 Antitrypsin Deficiency.

    Campos MA, Diaz AA

    Chest 2018; (153(5)):1240-1248 doi:10.1016/j.chest.2017.11.017.

    PMID: 29175361
  15. 15

    Small airways disease in patients with alpha-1 antitrypsin deficiency.

    Toumpanakis D, Usmani OS

    Respiratory medicine 2023; (211()):107222 doi:10.1016/j.rmed.2023.107222.

    PMID: 36965591
  16. 16

    Emphysema: looking beyond alpha-1 antitrypsin deficiency.

    Janssen R, Piscaer I, Franssen FME, Wouters EFM

    Expert review of respiratory medicine 2019; (13(4)):381-397 doi:10.1080/17476348.2019.1580575.

    PMID: 30761929
  17. 17

    Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort.

    Clark VC, Marek G, Liu C, et al.

    Journal of hepatology 2018; (69(6)):1357-1364 doi:10.1016/j.jhep.2018.08.005.

    PMID: 30138687
  18. 18

    SVIP regulates Z variant alpha-1 antitrypsin retro-translocation by inhibiting ubiquitin ligase gp78.

    Khodayari N, Wang RL, Marek G, et al.

    PloS one 2017; (12(3)):e0172983 doi:10.1371/journal.pone.0172983.

    PMID: 28301499
  19. 19

    Known Mutations at the Cause of Alpha-1 Antitrypsin Deficiency an Updated Overview of SERPINA1 Variation Spectrum.

    Seixas S, Marques PI

    The application of clinical genetics 2021; (14()):173-194 doi:10.2147/TACG.S257511.

    PMID: 33790624
  20. 20

    The Mechanism of Mitochondrial Injury in Alpha-1 Antitrypsin Deficiency Mediated Liver Disease.

    Khodayari N, Wang RL, Oshins R, et al.

    International journal of molecular sciences 2021; (22(24)) doi:10.3390/ijms222413255.

    PMID: 34948056
  21. 21

    Alpha-1 antitrypsin deficiency caused by a novel mutation (p.Leu263Pro): Pi*ZQ0gaia - Q0gaia allele.

    Oliveira MJ, Seixas S, Ladeira I, et al.

    Revista portuguesa de pneumologia 2015; doi:10.1016/j.rppnen.2015.07.002.

    PMID: 26281944
  22. 22

    Alpha-1 Antitrypsin Deficiency Screening Using Serum Protein Electrophoresis.

    Perales-Afán JJ, Menao S, García-Gutiérrez A, et al.

    Respiratory care 2025; (70(5)):551-558 doi:10.1089/respcare.12524.

    PMID: 39969926
  23. 23

    Alpha-1-Antitrypsin Deficiency: Disease Management and Learning from Studies.

    Greulich T

    COPD 2017; (14(sup1)):S8-S11 doi:10.1080/15412555.2017.1286166.

    PMID: 28306355
  24. 24

    [Alpha 1-antitrypsin deficiency].

    Mornex JF

    Revue des maladies respiratoires 2022; (39(8)):698-707 doi:10.1016/j.rmr.2022.02.062.

    PMID: 35715315
  25. 25

    Experimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency.

    Pye A, Turner AM

    Expert opinion on investigational drugs 2019; (28(10)):891-902 doi:10.1080/13543784.2019.1672656.

    PMID: 31550938

This page explains Alpha-1 Antitrypsin Deficiency genetics and lab terminology for educational purposes only. Always consult your pulmonologist or medical geneticist to interpret your specific lab results and health risks.

Get notified when new evidence is published on Alpha-1-antitrypsin deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.